These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23463207)

  • 41. Chemical genetics-based development of small molecules targeting hepatitis C virus.
    Jin G; Lee J; Lee K
    Arch Pharm Res; 2017 Sep; 40(9):1021-1036. PubMed ID: 28856597
    [TBL] [Abstract][Full Text] [Related]  

  • 42. New antiviral agents for hepatitis C.
    Pawlotsky JM
    F1000 Biol Rep; 2012; 4():5. PubMed ID: 22403588
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Directly acting antivirals (DAAs) for the treatment of chronic hepatitis C virus infection in liver transplant patients: "a flood of opportunity".
    Gane EJ; Agarwal K
    Am J Transplant; 2014 May; 14(5):994-1002. PubMed ID: 24730431
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Anti-HCV drugs in the pipeline.
    Yang PL; Gao M; Lin K; Liu Q; Villareal VA
    Curr Opin Virol; 2011 Dec; 1(6):607-16. PubMed ID: 22440918
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The history of hepatitis C virus (HCV): Basic research reveals unique features in phylogeny, evolution and the viral life cycle with new perspectives for epidemic control.
    Bukh J
    J Hepatol; 2016 Oct; 65(1 Suppl):S2-S21. PubMed ID: 27641985
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New therapies for chronic hepatitis C infection: a systematic review of evidence from clinical trials.
    Lee LY; Tong CY; Wong T; Wilkinson M
    Int J Clin Pract; 2012 Apr; 66(4):342-55. PubMed ID: 22420497
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.
    Lewis H; Cunningham M; Foster G
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):471-85. PubMed ID: 23199506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hepatitis C virus-specific directly acting antiviral drugs.
    Delang L; Neyts J; Vliegen I; Abrignani S; Neddermann P; De Francesco R
    Curr Top Microbiol Immunol; 2013; 369():289-320. PubMed ID: 23463206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
    Li X; Han J; Lee HW; Yoon YS; Jin Y; Khadka DB; Yang S; Kim M; Cho WJ
    Bioorg Med Chem; 2020 Oct; 28(19):115679. PubMed ID: 32912430
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.
    Ploss A; Dubuisson J
    Gut; 2012 May; 61 Suppl 1():i25-35. PubMed ID: 22504917
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New hepatitis C therapies in clinical development.
    Vermehren J; Sarrazin C
    Eur J Med Res; 2011 Jul; 16(7):303-14. PubMed ID: 21813371
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Avasimibe: A novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles.
    Hu L; Li J; Cai H; Yao W; Xiao J; Li YP; Qiu X; Xia H; Peng T
    Antiviral Res; 2017 Dec; 148():5-14. PubMed ID: 29074218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiviral resistance and specifically targeted therapy for HCV (STAT-C).
    Thompson AJ; McHutchison JG
    J Viral Hepat; 2009 Jun; 16(6):377-87. PubMed ID: 19472445
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Advances in the treatment of hepatitis C virus infection.
    Jesudian AB; Gambarin-Gelwan M; Jacobson IM
    Gastroenterol Hepatol (N Y); 2012 Feb; 8(2):91-101. PubMed ID: 22485076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Recent Advances in Antiviral Therapy for Chronic Hepatitis C.
    Tamori A; Enomoto M; Kawada N
    Mediators Inflamm; 2016; 2016():6841628. PubMed ID: 27022210
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Direct anti-HCV agents.
    Zhang X
    Acta Pharm Sin B; 2016 Jan; 6(1):26-31. PubMed ID: 26904396
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Selection of direct-acting antiviral agents for chronic hepatitis C infection].
    He YJ; Liu ZH; Hou JL
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):169-172. PubMed ID: 29804388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Have we significantly underestimated the capacity in the Australian health system to treat chronic hepatitis C infection in an interferon-free era?
    Kaan IA; Jones T; McCaughan GW
    Intern Med J; 2017 Mar; 47(3):269-274. PubMed ID: 27717117
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pushing to a cure by harnessing innate immunity against hepatitis C virus.
    Ireton RC; Gale M
    Antiviral Res; 2014 Aug; 108():156-64. PubMed ID: 24907428
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treating hepatitis C infection by targeting the host.
    Salloum S; Tai AW
    Transl Res; 2012 Jun; 159(6):421-9. PubMed ID: 22633094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.